In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tesaro nets $409mm through public offering

Executive Summary

Tesaro Inc. (oncology therapies) publicly sold 5.35mm common shares (including the overallotment) at $81 for net proceeds of $409mm. Some of the money will fund commercialization of Varubi (rolapitant) and rolapitant IV, both indicated for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. Proceeds will also support ongoing trials for niraparib (in Phase III for ovarian and breast cancers) and additional immuno-oncology projects in the company's pipeline.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies